| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
FIDSON Overview
Fidson Healthcare Plc engages in the manufacture and distribution of pharmaceutical products in Nigeria.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₦6.10 |
| 52 Week High | ₦3.72 |
| 52 Week Low | ₦6.50 |
| Beta | 0.26 |
| 1 Month Change | 0.16% |
| 3 Month Change | 0.16% |
| 1 Year Change | 63.98% |
| 3 Year Change | 12.96% |
| 5 Year Change | 342.03% |
| Change since IPO | 93.65% |
Recent News & Updates
Shareholder Returns
| FIDSON | NG Pharmaceuticals | NG Market | |
|---|---|---|---|
| 7D | 0.7% | 1.3% | 1.1% |
| 1Y | 64.0% | 34.3% | 38.9% |
Return vs Industry: FIDSON exceeded the NG Pharmaceuticals industry which returned 34.3% over the past year.
Return vs Market: FIDSON exceeded the NG Market which returned 38.9% over the past year.
Price Volatility
| FIDSON volatility | |
|---|---|
| FIDSON Beta | 0.26 |
| Industry Beta | 0.56 |
| Market Beta | 1 |
Stable Share Price: FIDSON is less volatile than 75% of NG stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: FIDSON's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 405 | Fidelis Ayebae | https://www.fidson.com |
Fidson Healthcare Plc engages in the manufacture and distribution of pharmaceutical products in Nigeria. The company operates through Over-the-Counter, Ethical Products, and Consumer segments. It offers drugs, injectables, and infusions.
Fidson Healthcare Fundamentals Summary
| FIDSON fundamental statistics | |
|---|---|
| Market Cap | ₦12.73b |
| Earnings (TTM) | ₦1.63b |
| Revenue (TTM) | ₦20.84b |
7.8x
P/E Ratio0.6x
P/S RatioIs FIDSON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FIDSON income statement (TTM) | |
|---|---|
| Revenue | ₦20.84b |
| Cost of Revenue | ₦11.52b |
| Gross Profit | ₦9.33b |
| Expenses | ₦7.70b |
| Earnings | ₦1.63b |
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.78 |
| Gross Margin | 44.76% |
| Net Profit Margin | 7.83% |
| Debt/Equity Ratio | 120.6% |
How did FIDSON perform over the long term?
See historical performance and comparisonDividends
4.1%
Current Dividend Yield32%
Payout RatioValuation
Is Fidson Healthcare undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FIDSON (NGN6.1) is trading below our estimate of fair value (NGN93.24)
Significantly Below Fair Value: FIDSON is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FIDSON is good value based on its PE Ratio (7.8x) compared to the African Pharmaceuticals industry average (9.4x).
PE vs Market: FIDSON is poor value based on its PE Ratio (7.8x) compared to the NG market (7.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FIDSON's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FIDSON is good value based on its PB Ratio (1.1x) compared to the XF Pharmaceuticals industry average (1.5x).
Future Growth
How is Fidson Healthcare forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
16.7%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if FIDSON's forecast earnings growth is above the savings rate (13.2%).
Earnings vs Market: Insufficient data to determine if FIDSON's earnings are forecast to grow faster than the NG market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: FIDSON's revenue (16.7% per year) is forecast to grow faster than the NG market (10.4% per year).
High Growth Revenue: FIDSON's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FIDSON's Return on Equity is forecast to be high in 3 years time (23.7%)
Past Performance
How has Fidson Healthcare performed over the past 5 years?
5.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FIDSON has high quality earnings.
Growing Profit Margin: FIDSON's current net profit margins (7.8%) are higher than last year (2.9%).
Past Earnings Growth Analysis
Earnings Trend: FIDSON's earnings have grown by 5.6% per year over the past 5 years.
Accelerating Growth: FIDSON's earnings growth over the past year (294.1%) exceeds its 5-year average (5.6% per year).
Earnings vs Industry: FIDSON earnings growth over the past year (294.1%) exceeded the Pharmaceuticals industry 10%.
Return on Equity
High ROE: FIDSON's Return on Equity (14.7%) is considered low.
Financial Health
How is Fidson Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: FIDSON's short term assets (NGN17.1B) exceed its short term liabilities (NGN11.9B).
Long Term Liabilities: FIDSON's short term assets (NGN17.1B) exceed its long term liabilities (NGN8.4B).
Debt to Equity History and Analysis
Debt Level: FIDSON's debt to equity ratio (120.6%) is considered high.
Reducing Debt: FIDSON's debt to equity ratio has increased from 43.9% to 120.6% over the past 5 years.
Debt Coverage: FIDSON's debt is well covered by operating cash flow (51.2%).
Interest Coverage: FIDSON's interest payments on its debt are not well covered by EBIT (2.8x coverage).
Balance Sheet
Dividend
What is Fidson Healthcare current dividend yield, its reliability and sustainability?
4.10%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: FIDSON's dividend (4.1%) is higher than the bottom 25% of dividend payers in the NG market (3.25%).
High Dividend: FIDSON's dividend (4.1%) is low compared to the top 25% of dividend payers in the NG market (7.24%).
Stability and Growth of Payments
Stable Dividend: FIDSON's dividend payments have been volatile in the past 10 years.
Growing Dividend: FIDSON's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (31.9%), FIDSON's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Fidelis Ayebae
no data
Tenure
Dr. Fidelis Akhagboso Ayebae serves as the Managing Director and Chief Executive Officer of Fidson Healthcare Plc. Dr. Ayebae has experience in corporate management having worked in Nigeria International B...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Fidson Healthcare Plc's employee growth, exchange listings and data sources
Key Information
- Name: Fidson Healthcare Plc
- Ticker: FIDSON
- Exchange: NGSE
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₦12.727b
- Shares outstanding: 2.09b
- Website: https://www.fidson.com
Number of Employees
Location
- Fidson Healthcare Plc
- 268, Ikorodu Road
- Obanikoro
- Lagos
- Nigeria
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/19 15:21 |
| End of Day Share Price | 2021/10/18 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.